SNGX News and Press, Soligenix Inc. From 10/22/20

Additional data from Phase 3 Flash trial evaluating Soligenix's ([[SNGX]] +6.4%) SGX301 (synthetic hypericin) in patients with cutaneous T-cell lymphoma ((CTCL)), has reinforced positive primary endpoint treatment response demonstrated in treatment cycle 1, with further improved response...

Soligenix Announces Phase 3 FLASH Study Continues to Demonstrate Positive Benefits in Patients with Cutaneous T-Cell Lymphoma - Nearly half of all patients in Phase 3 trial continue to see sustained and statistically significant improvement in their response rates when treated w...

Soligenix to Present at the BIO Investor Forum PR Newswire PRINCETON, N.J., Oct. 8, 2020 PRINCETON, N.J. , Oct. 8, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developin...

Eli Lilly reports positive data for Phase 3 monarchE trial. Soligenix gets boost from Filovirus vaccine antigens data. Ayala Pharmaceuticals posts encouraging interim data for AL101. For further details see: Eli Lilly Reports MonarchE Data, And Other News: The Good, Bad ...

New York, New York--(Newsfile Corp. - September 21, 2020) - Soligenix's (NASDAQ: SNGX) RiVax® program is in focus after a failed attempt to send ricin-laced letters to the White House last week raised fresh concerns about the deadly toxin. Those letters, including others addressed to...

Soligenix (NASDAQ: SNGX )   perks up 8%  premarket on heels of the publication of nonclinical results characterizing filovirus protein antigens (including for Ebola and Marburg viruses) and their thermostabilization. More news on: Soligenix, Inc., Healthcare stocks news, Stock...

PRINCETON, N.J. , Sept. 15, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publ...

PRINCETON, N.J. , Sept. 10, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, released the presentatio...

PRINCETON, N.J. , Sept. 9, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its P...

Kensington Capital Acquisition (KCAC) +39%  as QuantumScape goes public via Kensington Capital merger. More news on: FibroGen, Inc., Fulgent Genetics, Inc., Soligenix, Inc., Stocks on the move, , Read more ...